Dogwood Therapeutics, Inc.
DWTX
$1.84
$0.010.55%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 62.55% | 14.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.86% | -75.92% | |||
| Operating Income | -32.86% | 75.92% | |||
| Income Before Tax | -32.99% | 76.19% | |||
| Income Tax Expenses | -96.23% | 2,371.43% | |||
| Earnings from Continuing Operations | -31.91% | 75.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.91% | 75.99% | |||
| EBIT | -32.86% | 75.92% | |||
| EBITDA | -32.84% | 75.92% | |||
| EPS Basic | 42.87% | 96.83% | |||
| Normalized Basic EPS | 42.37% | 96.86% | |||
| EPS Diluted | 42.87% | 96.83% | |||
| Normalized Diluted EPS | 42.37% | 96.86% | |||
| Average Basic Shares Outstanding | 131.01% | 656.55% | |||
| Average Diluted Shares Outstanding | 131.01% | 656.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||